Edwards Lifesciences Co. (NYSE:EW) Holdings Trimmed by Radnor Capital Management LLC

Radnor Capital Management LLC reduced its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 8.9% during the fourth quarter, Holdings Channel.com reports. The fund owned 21,670 shares of the medical research company’s stock after selling 2,114 shares during the quarter. Radnor Capital Management LLC’s holdings in Edwards Lifesciences were worth $1,604,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. FSA Wealth Management LLC acquired a new position in shares of Edwards Lifesciences in the 3rd quarter worth approximately $30,000. Prospera Private Wealth LLC bought a new position in shares of Edwards Lifesciences in the third quarter valued at $32,000. Avior Wealth Management LLC increased its holdings in shares of Edwards Lifesciences by 138.7% in the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after buying an additional 308 shares in the last quarter. Peoples Bank KS acquired a new position in shares of Edwards Lifesciences in the 3rd quarter valued at $40,000. Finally, JFS Wealth Advisors LLC lifted its stake in Edwards Lifesciences by 31.1% during the third quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock valued at $46,000 after buying an additional 166 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Price Performance

NYSE:EW opened at $71.05 on Wednesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12. The company has a fifty day moving average price of $71.82 and a 200 day moving average price of $71.62. The stock has a market cap of $41.91 billion, a P/E ratio of 10.25, a PEG ratio of 3.61 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, meeting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The business had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. During the same quarter in the prior year, the business earned $0.59 earnings per share. The firm’s revenue for the quarter was up 8.9% on a year-over-year basis. Analysts anticipate that Edwards Lifesciences Co. will post 2.56 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently commented on EW shares. Stifel Nicolaus raised their target price on Edwards Lifesciences from $70.00 to $75.00 and gave the stock a “hold” rating in a research report on Thursday, December 5th. Truist Financial reissued a “hold” rating and issued a $78.00 price target (up from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. Daiwa America lowered shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 30th. Royal Bank of Canada lifted their price target on Edwards Lifesciences from $80.00 to $85.00 and gave the company an “outperform” rating in a report on Thursday, December 5th. Finally, Barclays lifted their target price on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the company an “overweight” rating in a research note on Monday, December 2nd. Sixteen research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $79.40.

Insiders Place Their Bets

In other news, VP Daniel J. Lippis sold 2,500 shares of the firm’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $74.08, for a total transaction of $185,200.00. Following the completion of the transaction, the vice president now directly owns 23,189 shares of the company’s stock, valued at approximately $1,717,841.12. This trade represents a 9.73 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total transaction of $327,850.00. Following the sale, the vice president now owns 46,936 shares in the company, valued at approximately $3,077,593.52. This trade represents a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 32,500 shares of company stock worth $2,160,800. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.